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Background: Stereotactic body radiation therapy (SBRT) delivers high doses of  radiation 
to the prostate while minimizing radiation to the adjacent critical organs. Large fraction 
sizes may increase urinary morbidity due to unavoidable treatment of the prostatic 
urethra. This study reports rates of acute urinary morbidity following SBRT for localized 
prostate cancer with prophylactic alpha-adrenergic antagonist utilization and urethral 
dose reduction (UDR).
Methods: From April 2013 to September 2014, 102 patients with clinically localized 
prostate cancer were treated with robotic SBRT to a total dose of 35–36.25 Gy in five 
fractions. UDR was employed to limit the maximum point dose of the prostatic urethra 
to 40 Gy. Prophylactic alpha-adrenergic antagonists were initiated 5 days prior to SBRT 
and continued until resolution of urinary symptoms. Quality of life (QoL) was assessed 
before and after treatment using the American Urological Association Symptom Score 
(AUA) and the Expanded Prostate Cancer Index Composite-26 (EPIC-26). Clinical signif-
icance was assessed using a minimally important difference (MID) of one half SD change 
from baseline.
results: One hundred two patients underwent definitive prostate SBRT with UDR and 
were followed for 3 months. No patient experienced acute urinary retention requiring 
catheterization. A mean baseline AUA symptom score of 9.06 significantly increased to 
11.83 1-week post-SBRT (p = 0.0024) and 11.84 1-month post-SBRT (p = 0.0023) but 
Abbreviations: 3-T, 3-Tesla; ADT, androgen deprivation therapy; AUA, American Urological Association; CTV, clinical target 
volume; DIL, dominant intraprostatic lesion; DVH, dose–volume histogram; EBRT, external beam radiation therapy; EPIC-26, 
expanded prostate index composite; IMRT, intensity-modulated radiation therapy; LDR, low-dose rate; PET, positron emission 
tomography; PTV, planning target volume; QoL, quality of life; SBRT, stereotactic body radiation therapy.
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returned to baseline by 3 months. A mean baseline EPIC-26 irritative/obstructive score 
of 87.7 decreased to 74.1 1-week post-SBRT (p < 0.0001) and 77.8 1-month post-
SBRT (p < 0.0001) but returned to baseline at 3 months. EPIC-26 irritative/obstructive 
score changes were clinically significant, exceeding the MID of 6.0. At baseline, 8.9% of 
men described their urinary function as a moderate to big problem, and that proportion 
increased to 37.6% 1 week following completion of SBRT before returning to baseline 
by 3 months.
conclusion: Stereotactic body radiation therapy for localized prostate cancer with 
utilization of prophylactic alpha-adrenergic antagonist and UDR was well tolerated as 
determined by acute urinary function and bother, and symptoms were comparable to 
those observed following conventionally fractionated external beam radiation therapy 
(EBRT). Longer follow-up is required to assess long-term toxicity and efficacy following 
SBRT with UDR.
Keywords: sBrT, cyberKnife, prostate cancer, quality of life, expanded prostate index composite, urethral dose 
reduction, aUa symptom score
inTrODUcTiOn
Treatment of localized prostate cancer with definitive stereotactic 
body radiation therapy (SBRT) has become an accepted alternative 
to conventionally fractionated external beam radiation therapy 
(EBRT). However, acute urinary symptoms, such as frequency (1), 
weak stream (2), and dysuria (3), are common to both modalities 
during and after treatment due to the proximity of genitourinary 
structures (4). Patient comorbidities and large prostate volumes 
may increase the risk for symptoms (5–10), and neoadjuvant 
androgen deprivation may lessen their incidence and severity in 
patients treated with brachytherapy (11). Technical factors, such 
as the radiation dose to the bladder and urethra, as well as overall 
treatment time, may also impact the severity of such symptoms 
(12–15). Alpha-adrenergic antagonists are commonly used 
to manage urinary symptoms during and following radiation 
therapy (16), and clinical trials have suggested that prophylactic 
alpha-antagonists may decrease the peak severity and duration 
of urinary voiding symptoms following brachytherapy (17, 18).
The pattern of acute urinary toxicity following SBRT appears 
similar to that of conventionally fractionated EBRT and brachy-
therapy (19). Many patients suffer from acute urinary symptoms, 
whereas a minority of patients experience moderate to severe 
late symptoms (20). Following SBRT, acute urinary symptom 
scores peak 1 week after the completion of treatment (21) and 
return to baseline by 3 months. However, a minority of patients 
experience a clinically meaningful increase in their urinary 
symptoms >6  months after the completion of treatment (22). 
Late urinary symptom flare is associated with high bladder 
doses, inhomogeneous plans, and high prostatic urethral doses 
(23–25). This late urinary symptom flare resolves with conserva-
tive management (22).
Late urinary symptom flare may result from the high prostatic 
urethral doses seen in relatively inhomogeneous SBRT plans 
(20). Previous studies of urethral sparing with both EBRT and 
brachytherapy have demonstrated unacceptable levels of local 
recurrence (26). Urethral dose reduction (UDR) aims to reduce 
the risk of late urinary toxicity without significantly increasing the 
risk of local recurrence (27). Urethral catheter (UC) placement 
prior to simulation is a commonly used technique to identify 
the prostatic urethra. This approach is invasive, increases patient 
discomfort, and may increase the risk of iatrogenic urethral 
strictures. Furthermore, UC placement may distort the urethral 
anatomy, resulting in possible planning inaccuracies (28). Simple 
surrogates, such as a cylinder at the geometric center of the 
prostate, are especially inaccurate at the base (29). 3-T magnetic 
resonance imaging (MRI) provides an ideal non-invasive proce-
dure to accurately identify the position of the urethra (30).
We have modified our institutional protocol to incorpo-
rate prophylactic alpha-adrenergic antagonists and limit the 
maximum urethral point dose to 110% of the prescription dose 
(40 Gy), as previously described for brachytherapy (31) with the 
aid of 3-T MRI. We aim to reduce the incidence and severity of 
urinary symptoms without a concomitant increased risk of local 
failure. In this study, we describe our current treatment approach 
and report our acute urinary toxicity outcomes for patients 
undergoing UDR with prophylactic alpha-adrenergic antagonist 
utilization.
MaTerials anD MeThODs
Patient selection
Patients eligible for study inclusion had prostate cancer treated 
with SBRT with prophylactic alpha-adrenergic antagonist use and 
UDR at MedStar Georgetown University Hospital. All patients 
provided informed consent prior to treatment. The Georgetown 
University Internal Review Board (IRB) approved this single 
institution prospective quality of life (QoL) study (IRB 12-1175).
sBrT Treatment Planning and Delivery
Stereotactic body radiation therapy treatment planning and 
delivery were performed, as previously described (32) with 
TaBle 1 | Dose targets and constraints for treatment planning.
36.25 gy plan constraints
PTV max dose 120% of 36.25 Gy (43.5 Gy)
PTV V (36.25 Gy) ≥95%
CTV V (36.25 Gy) ≥99%
Prostatic urethra V (36.25 Gy) ≥95%
V (40 Gy) ≤0.03 cc
Membranous urethra V (37 Gy) <50%
Bladder V (37 Gy) <5 cc
V (100%) <10%
V (50%) <40%
Rectum V (36 Gy) <1 cc
V (100%) <5%
V (90%) <10%
V (80%) <20%
V (75%) <25%
V (50%) <40%
Sigmoid colon V (30 Gy) <1 cc
Penile bulb V (29.5 Gy) <3 cc
Testicles D (20%) <2 Gy
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modifications as follows. Gold fiducials were placed into the 
prostate under trans-rectal ultrasound guidance. For treatment 
planning, thin-cut computed tomography (CT) images were 
fused with high-resolution 3-T magnetic resonance (MR) images 
obtained without an endorectal coil. MR images were obtained 
using a 180-mm field of view, with an in-plane spatial resolution 
of 9 by 7 mm, and a through-plane spatial resolution of 3 mm. 
Accuracy of MR-CT fusion was verified by the treating physi-
cian (Sean P. Collins) prior to contouring or treatment planning. 
The prostatic urethra was identified on MR images using pre-
contrast T2-weighted sequences and post-contrast T1-weighted 
sequences. The clinical target volume (CTV) included the prostate 
and proximal seminal vesicles. The planning target volume (PTV) 
included a 3-mm (inferior, superior, and posterior) or 5-mm 
(anterolateral) expansion around the CTV. A dose of 35–36.25 Gy 
was prescribed to the PTV in five fractions. The bladder, prostatic 
urethra, and membranous urethra were separately contoured 
and evaluated with dose–volume histogram (DVH) analysis to 
meet pre-specified planning objectives (Table 1) using Multiplan 
(Accuray Inc., Sunnyvale, CA, USA). The prostatic urethra was 
contoured on T2-weighted MRI sequences, and a planning risk 
volume (PRV) expansion was not employed. Treatment plans 
consist of hundreds of pencil beams using the IRIS variable aper-
ture collimator (Accuray Inc., Sunnyvale, CA, USA). Plans were 
inhomogeneous by design to maximize dose to the prostate and 
to minimize dose to adjacent critical structures. The prescription 
isodose line was set at a minimum of 80% to limit the prostatic 
urethral dose such that the volume receiving 40 Gy was <0.03 cc. 
Radiation was delivered in treatments of approximately 40 min 
duration using the CyberKnife Radiosurgical System (Accuray 
Inc., Sunnyvale, CA, USA) every other day over the course of 
11  days in total. Target position was confirmed multiple times 
during each treatment with a minimum of three properly placed 
fiducials (33). Prophylactic alpha-adrenergic antagonists were 
initiated 5 days prior to SBRT and continued until resolution of 
urinary symptoms. Bothersome urinary symptoms arising  during 
or following treatment were managed with alpha-adrenergic 
antagonist dose increases from 0.4 to 0.8  mg daily if deemed 
necessary by the treating physician (Sean P. Collins). Refractory 
symptoms were treated with a short dexamethasone taper (2 mg 
daily for 7 days followed by 1 mg daily for 7 days).
Follow-up and statistical analysis
Overall health-related QoL was assessed at baseline using the 
EQ-5D survey with higher values indicating better QoL (34). 
Patients completed a paper questionnaire including the American 
Urological Association Symptom Index (AUA) (35) and the 
Expanded Prostate Cancer Index Composite-26 (EPIC-26) (36) 
on the day of the first SBRT fraction and during routine follow-up 
1 and 3  months after the SBRT completion. One week follow-
ing the completion of treatment, surveys were administered 
via phone interview by the study nurse practitioner (Thomas 
M. Yung). AUA scores range from 0 to 35 with higher values 
representing worsening urinary symptoms. To compare changes 
between time points, responses were assigned a score, and the 
significance of mean score changes was assessed by paired t-test. 
The EPIC-26 is a validated survey that measures urinary func-
tion and bother. Responses to the EPIC-26 questionnaire were 
grouped by physiologic domains and assigned numerical scores. 
The multi-item scale scores were transformed linearly to a 0–100 
scale, as recommended in the scoring instructions for the EPIC-
26. Lower numbers correspond to worse function and increased 
bother. The paired t-test and Wilcoxon signed-rank test were 
used to assess significance of the change in scores. For each physi-
ologic domain question (Questions 4a–e) and the overall urinary 
bother question (Question 5), responses were grouped into three 
clinically relevant categories (no problem, very small to small 
problem, and moderate to big problem). Chi-square analysis was 
used to assess significance of proportional changes in each of the 
clinically relevant categories. The minimally important difference 
(MID), which is used to assess clinically significant change from 
baseline, was set as a half SD of the baseline mean (37).
resUlTs
One hundred two patients with localized prostate cancer were 
treated with SBRT and followed for 3 months to evaluate acute 
toxicities. The median patient age was 69 years old (range: 48–84), 
and the median prostate volume was 36.0 cc (range: 16.6–125). 
Using the D’Amico risk classification, 17.6% of patients were low 
risk, 67.6% of patients were intermediate risk, and 14.7% patients 
were high risk. The majority of patients (63%) were treated with 
36.25 Gy in 7.25 Gy fractions, while the remainder received 35 Gy 
in 7 Gy fractions (Table 2). The mean number of beams used for 
each fraction was 153.5 (range: 125–186) with a mean plan homo-
geneity index of 1.20 (range: 1.19–1.22). The mean prescription 
isodose line was 83.03% (range: 82–84%), and the mean planned 
fraction length was 39.05 min (range: 35–43 min). All patients 
met pre-specified planning objectives (Table 1). Representative 
3-T MR and CT images show the prostatic urethra located 
centrally at the apex with anterior deviation as it approaches the 
bladder neck (Figures 1 and 2).
FigUre 1 | Treatment planning axial T2-weighted Mr (a–c) and axial cT (D–F) images demonstrating the prostatic urethra and rectum. (a,D) Axial 
plane, 0.5 cm cranial to apex. (B,e) Axial plane, mid-prostate level. (c,F) Axial plane, 1 cm caudal to base.
TaBle 2 | Baseline patient characteristics.
Baseline characteristics all (n = 102)
Age (years) Median age (range) 69 (48–84)
Race White 56.9%
Black 30.4%
Other 12.7%
Gleason score 6 29.4%
7 59.8%
8 9.8%
9 1.0%
T stage T1 66.7%
T2 32.4%
T3 1.0%
D’Amico risk group Low 17.6%
Intermediate 67.6%
High 14.7%
Prostate volume Median volume (cc) (range) 36.0 (16.6–125.0)
CCI 0 54.9%
1 25.5%
2+  19.6%
Pre-treatment PSA Median PSA (ng/mL) (range) 7.15 (2.20–50.00)
Pre-treatment 
testosterone
Median testosterone (ng/dL) 
(range)
337 (3–990)
SBRT dose 35 Gy 36.6%
36.25 Gy 63.4%
ADT Yes 16.8%
No 83.2%
AUA severity Mild 46.1%
Moderate 50.0%
Severe 3.9%
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Consistent with a healthy elderly population, the mean 
baseline EQ VAS was 82.5 (Table 3). Baseline EPIC-26 urinary 
domain and AUA scores show that the majority of patients had 
mild to moderate lower urinary tract symptoms prior to receiving 
SBRT (Table 3). The mean AUA symptom score at 1 week and at 
1 month post-treatment increased from 9.06 to 11.83 (p = 0.0024) 
and 11.84 (p = 0.0024), respectively (Table 4; Figure 3), although 
these statistically significant increases were of borderline clini-
cal significance (MID = 2.87). The mean AUA score essentially 
returned to baseline at 3 months (Table 4; Figure 3).
Mean changes in EPIC-26 urinary domain-specific scores 
from baseline are shown in Table 4 and Figure 4. The EPIC-26 
irritative/obstructive score decreased at 1  week and 1  month 
with a mean change of −13.6 (p < 0.0001) and −9.9 (p < 0.0001), 
respectively, post-SBRT. These declines were both statistically and 
clinically significant (MID =  6.0, Figure 4A). The EPIC irrita-
tive/obstructive score returned to baseline by 3  months (mean 
change = +0.18, p = 0.25) (Table 4; Figure 4A). There was no 
clinically significant change in the EPIC incontinence score during 
the first 3 months following SBRT (Table 4; Figure 4B). The EPIC 
urinary bother score declined transiently at 1 week and 1 month, 
with mean changes of −24.3 (p < 0.0001) and −14.1 (p < 0.0001), 
respectively, following treatment (Table 4). These declines were 
both statistically and clinically significant (MID  =  11.9). By 
3 months post-SBRT, clinically significant changes had resolved, 
as the EPIC urinary bother score returned to baseline levels 
(mean change = −1.5, p = 0.12) (Table 4; Figure 5).
Patient-reported responses for urinary incontinence and 
hematuria did not show clinically significant changes from 
TaBle 3 | Pre-treatment Qol scores.
Pre-treatment quality of life (Qol) scores
Mean sD MiD
Baseline eQ-5D (n = 101)
EQ-5D index 0.916 0.090 0.045
EQ VAS 82.5 14.29 7.14
Baseline ePic-26 urinary domains (n = 101)
Incontinence 91.6 13.16 6.58
Irritative/obstructive 87.7 12.00 6.00
Bother 78.0 23.79 11.90
Baseline aUa scores (n = 102)
Total score 9.06 5.74 2.87
FigUre 2 | Treatment planning axial cT images demonstrating the 
prostatic urethra (dark red line), prostate (red line), and rectum 
(brown line). Isodose lines shown are as follows: 108% of the prescription 
dose (yellow line), 100% of the prescription dose (cyan line), 75% of the 
prescription dose (dark blue line), 50% of the prescription dose (green line).
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baseline, while urinary retention and urinary frequency increased 
significantly 1-week and 1-month post-SBRT but returned to base-
line by 3 months (Table 5). Dysuria increased significantly and 
improved, but did not return to baseline, by 3 months following 
completion of SBRT (Table 5). Regarding overall urinary bother 
(Question 5 of the EPIC-26), 50.5% of our cohort reported some 
level of bother due to urinary symptoms, and 8.9% of patients 
reported that urinary symptoms were a moderate to big problem. 
One week and 1 month following SBRT, 37.6% (p < 0.0001) and 
18.2% (p < 0.0002) of our cohort reported that overall urinary 
bother was a moderate to big problem (Table 6). Patient-reported 
urinary bother returned to baseline by 3  months, with 8.0% 
(p =  0.66) of the cohort reporting a moderate to big problem. 
Radar plots summarize the time course of individual symptom 
bother before and after SBRT in Figure 6. Urinary frequency and 
weak stream bother peak at 1 week and gradually return to base-
line by 3  months following completion of SBRT, while dysuria 
peaks at 1 week and improves but does not return to baseline by 
3 months. Table 7 summarizes urinary morbidity data at 1 and 
3 months for relevant brachytherapy and SBRT series.
DiscUssiOn
Most patients develop acute voiding symptoms which peak 
1–2  weeks following SBRT for localized prostate cancer (20). 
Although evidence for early urinary morbidity is growing (44), 
this study is among the first to comprehensively assess urinary 
morbidity at 1  week following SBRT. We have prospectively 
employed several approaches to minimize urinary symptoms 
following SBRT. The overall treatment time has been extended 
from 5 to 11 days (15), prophylactic alpha-adrenergic antagonist 
use was initiated prior to treatment, and the maximum point 
dose to the prostatic urethra was limited to <40 Gy. Our prior 
treatment approach allowed for central prostatic point doses up 
to 45 Gy (20). Given reports of high rates of treatment failure with 
urethral-sparing approaches (26), we designed our current UDR 
approach to maintain excellent disease control while reducing 
late urinary toxicity.
In this study, we report a small statistically significant increase 
in the AUA score 1 week following SBRT. However, the increase of 
approximately three points was of borderline clinical significance 
and compares favorably with prior trials (21). Consistent with 
previous reports from our institution (20) and others (45), the 
mean AUA score remained elevated 1-month post-treatment and 
returned to baseline by 3 months. It is significant that the peak 
rise and duration of post-SBRT AUA score elevations was less 
than reported for patient receiving prophylactic alpha agonists 
for low-dose rate (LDR) brachytherapy (18, 46). Furthermore, 
TaBle 4 | changes in ePic-2 urinary summary and overall urinary bother scores following sBrT for prostate cancer.
Patient-reported quality of life from ePic-26 urinary bother domains and aUa score
1 week post-treatment 1 month post-treatment 3 months post-treatment
Mean change sD p-Value Mean change sD p-Value Mean change sD p-Value
ePic-26 domain (n = 101) (n = 99) (n = 88)
Incontinence +2.2 13.80 0.0496* −2.6 15.54 0.0429* −0.65 13.55 0.2234
Irritative/obstructive −13.6 17.40 <0.0001* −9.9 15.96 <0.0001* +0.18 11.27 0.2451
Urinary bother −24.3 30.90 <0.0001* −14.1 26.54 <0.0001* −1.5 23.17 0.1193
aUa score (n = 102) (n = 99) (n = 88)
Total score +2.73 7.1 0.0024* +2.74 6.95 0.0024* −0.9 5.4 0.2786
Changes in scores that are statistically significant are marked with an asterisk. 
FigUre 4 | Mean ePic-26 urinary irritative/obstructive (a) and incontinence (B) scores following sBrT for prostate cancer. EPIC-26 scores range from 
0 to 100 with lower values representing worse symptoms. Thresholds for clinically significant changes in scores (half SD above and below the baseline) are marked 
with dashed lines.
FigUre 3 | Mean aUa scores in total at baseline and following sBrT for prostate cancer. AUA scores range from 0 to 35 with higher values representing 
worse urinary symptoms. The thresholds for clinically significant changes in scores (half SD above and below the baseline) are marked with dashed lines. Error bars 
indicate 95% confidence intervals.
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these results indicate that QoL outcomes at 1 week are similar to 
those at 1 month following completion of SBRT, suggesting that 
early follow-up is redundant. Despite an apparent lack of util-
ity for research purposes, we have maintained the institutional 
policy to call patients 1 week following SBRT to optimize medical 
management and provide reassurance if needed.
We have reported an SBRT-induced increase in acute urinary 
irritative and obstructive symptoms with little impact on urinary 
continence. The EPIC irritative/obstructive score decreased at 
1 week and 1 month following treatment, with a return to baseline 
by 3  months. There was no clinically significant change in the 
EPIC incontinence domain during the first 3 months following 
SBRT. Although dysuria increased significantly from baseline 
and did not resolve at 3  months following SBRT, anecdotal 
clinical evidence suggests that dysuria tends to take more time 
to resolve than other urinary symptoms, which may account for 
FigUre 5 | Mean ePic-26 overall urinary bother score (Question 5) following sBrT. EPIC scores range from 0 to 100 with lower values representing worse 
symptoms. Thresholds for clinically significant changes in scores (half SD above and below the baseline) are marked with dashed lines.
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TaBle 5 | Urinary symptoms following sBrT.
Baseline 1 week 1 month 3 months
number (n) 101 101 99 88
Urinary incontinence
No problem (%) 71.3 81.2 60.6 62.5
Very small-small problem (%) 27.7 13.9 35.4 36.4
Moderate-big problem (%) 1.0 5.0 4.0 1.1
p-Value 0.6420 0.0066* 0.0637
Dysuria
No problem (%) 92.1 46.5 51.5 75.0
Very small-small problem (%) 5.9 36.6 41.4 25.0
Moderate-big problem (%) 2.0 16.8 6.1 0.0
p-Value <0.0001* <0.0001* 0.0039*
hematuria
No problem (%) 94.0 100.0 96.0 98.9
Very small-small problem (%) 5.0 0.0 4.0 1.1
Moderate-big problem (%) 1.0 0.0 0.0 0.0
p-Value 0.0313* 0.3750 0.1250
Urinary retention
No problem (%) 56.4 48.5 40.4 55.7
Very small-small problem (%) 40.6 33.7 45.5 43.2
Moderate-big problem (%) 3.0 17.8 14.1 1.1
p-Value 0.0002* 0.0002* 0.7713
Urinary frequency
No problem (%) 33.7 24.8 19.2 35.2
Very small-small problem (%) 53.5 33.7 53.5 51.1
Moderate-big problem (%) 12.9 41.6 27.3 13.6
p-Value <0.0001* <0.0001* 0.7246 
Patient-reported responses to EPIC-26 questions 4A (dripping), 4B (dysuria), 
4C (Hematuria), 4D (weak stream or incomplete emptying), and 4E (frequency).
Changes in scores that are statistically significant are marked with an asterisk.
TaBle 6 | Overall urinary bother following sBrT.
Baseline Day 7 Month 1 Month 3
number (n) 101 101 99 88
Urinary bother
No problem (%) 40.6 19.8 21.2 35.2
Very small–small problem (%) 50.5 42.6 60.6 56.8
Moderate-big problem (%) 8.9 37.6 18.2 8.0
p-Value <0.0001* 0.0002* 0.6567
Patient-reported responses to EPIC-26 Question 5.
Changes in scores that are statistically significant are marked with an asterisk.
this observation. However, overall urinary bother may be more 
important to the patient than specific urinary symptoms. We 
found that moderate to severe overall urinary bother increased 
following SBRT from a baseline of 8.9–37.6% 1 week following 
treatment. As seen with conventionally fractionated EBRT, this 
increase in urinary bother decreased at 1  month and returned 
to baseline by 3 months following completion of treatment (19).
Urethral dose reduction does not eliminate acute urinary 
 morbidity following SBRT, and dose effects on other genitourinary 
structures may serve as better predictors of acute urinary toxicity. 
In a study of patients undergoing LDR brachytherapy, bladder 
neck D2 cc was a better predictor of acute urinary toxicity than 
typically employed dose–volume constraints for the prostatic 
urethra (14). However, the goal of UDR is to improve long-term 
patient QoL, specifically by mitigating urinary symptom flare 
occurring at 12 months post-SBRT (20, 22). With longer follow-
up of this patient cohort, we will examine the effects of UDR on 
the incidence and severity of late urinary symptom flare. Future 
8Repka et al. SBRT with Urethral Dose Reduction
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FigUre 6 | radar plots showing the distribution of individual symptom bother following sBrT for prostate cancer. EPIC-26 scores range from 0 to 100 
with lower values representing worse symptoms. Points further from center indicate higher levels of bother for a given symptom. EPIC-26 question number is shown 
in parentheses.
TaBle 7 | comparison of published aUa score changes following brachytherapy and sBrT.
reference N Modality Total dose  
(gy)
no. of 
fractions
Urethral  
dose
Baseline 
aUa score
1-week aUa 
score
1-month aUa 
score
3-month aUa 
score
long-term 
aUa score
Henderson 
et al. (38)
255 LDR ± EBRT 145 (110 + 45) n/a Mean 
D10 = 232 Gy
6 n/r 19 (6 weeks) 15 5 (2 years)
Van Gellekom 
et al. (39)
127 LDR D90 = 133.0 
(mean)
n/a Mean 
D5 = 270 Gy
7.3 n/r 19.8 15.2 (6 months) 10.4 (2 years)
Williams et al. (40) 173 LDR D90 = 136.5 
(median)
n/a Mean 
Dmax = 219 Gy
5.5 n/r 17.1 14.4 8.0 (1 year)
Crook et al. (10) 150 LDR 145 n/a Mean 
Dmax = 209 Gy
6 n/r 13 13 3 (2 years)
Meier et al. (41) 295 SBRT 40 5 n/r 7.6 14.2 11.6 7.5 6.4 (4 years)
Tree et al. (42) 51 SBRT 36.25 5 n/r 6 11 
(1–3 weeks)
8 (4–6 weeks) 5 (7–12 weeks) n/r
Rana et al. (43) 102 SBRT 35–40 5 n/r 10.5 n/r 13.4 10.6 8.6 (3 years)
Present study 102 SBRT 35–36.25 5 Dmax < 40 Gy 9.1 11.8 11.8 8.2 n/r
n/r, not reported; n/a, not applicable.
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studies should further illuminate the nature of urinary morbidity 
secondary to prostatic urethral dose. For example, RTOG 0938, 
a multi-institutional randomized trial of SBRT versus moderate 
hypofractionation, required limitation of the urethra to 107% of 
prescription dose. Our report, in conjunction with other emerg-
ing data (44), portend well for continued improvement in the 
therapeutic ratio for prostate SBRT.
Recently reported results from the PATRIOT trial, which 
randomized patients to an every-other-day (11 days in total) 
or once-weekly (29  days in total) fractionation scheme, sug-
gest that extension of total treatment time to 1  month may 
decrease acute urinary morbidity (47). In our experience, 
extending overall treatment times beyond 2 weeks is unneces-
sary and may be burdensome to some patients. Importantly, 
the PATRIOT trial did not show an increase in irreversible 
late morbidity in the 11-day group. Furthermore, our 11-day 
treatment regimen was well tolerated with no patient requir-
ing catheterization; patients’ symptoms were short lived and 
resolved with conservative medical management. Our study 
shows that an 11-day SBRT treatment course with prophylactic 
alpha-adrenergic antagonist use and UDR is well tolerated 
with regard to acute urinary toxicity. Further follow-up of this 
cohort will be necessary to evaluate late urinary toxicity and 
ensure equivalent treatment efficacy to SBRT without UDR for 
localized prostate cancer.
cOnclUsiOn
Stereotactic body radiation therapy for clinically localized 
prostate cancer with UDR and prophylactic alpha-adrenergic 
antagonist use was well tolerated with acute urinary function and 
bother comparable to conventionally fractionated EBRT. In the 
first 3 months following treatment, the impact of SBRT on urina-
tion was minimal. Longer follow-up will be required to assess 
long-term morbidity and efficacy following SBRT with UDR.
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